CPMC Researchers Identify Drug Combinations to Counter Immunotherapy Resistance in Advanced Melanoma

Researchers at California Pacific Medical Center (CPMC) in San Francisco have identified potential therapeutic strategies for patients with advanced melanoma who no longer respond to immunotherapy. The findings address a significant challenge in cancer treatment, as resistance to immunotherapy remains a critical barrier for many patients with this aggressive form of skin cancer.

The study highlights the use of specific drug combinations that may help overcome immunotherapy resistance and potentially reactivate the immune system’s ability to target melanoma cells. Advanced melanoma often becomes unresponsive to standard treatments, leaving limited options for patients. Researchers at CPMC focused on exploring alternative approaches that could restore the effectiveness of the immune response against tumors. The findings represent an important step toward addressing one of oncology’s most urgent clinical needs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 16, 2025

Related posts:

Study Finds Racial Minorities Diagnosed with Early-Onset Colorectal Cancer at More Advanced Stages FDA Withdraws Defense of LDT Rule Amid Speculation Over Increased Focus on RUO Products Dutch Researchers Develop AI-Assisted Mammography Screening Method Reducing Radiologist Workload by 38% Advocacy Group Urges HHS to Release Withheld Study on Alcohol-Related Harms

Author

Mark Chiang